The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $3.2 million in grants to four life and bioscience projects in the Commonwealth of Virginia. These projects were awarded in Grant Round 17.
“The Catalyst works to help industry partners and academic investigators to raise follow-on funding” said Mike Grisham, CEO of Virginia Catalyst. Through this 17th round of funding, Virginia Catalyst has awarded 69 grants totaling over $36 million, resulting in over $54 million in matching funds and over $700 million in follow-on funding to date.
The Virginia Catalyst in now accepting Letters of Intent for Grant Round 18, until March 14th.
For more information visit: https://www.VirginiaCatalyst.org/apply.html
Grant Round 17 project awardees:
Project: Adenosine A2B receptor blockade for the treatment of Clostridium difficile infection (CDI) •Company: Adovate, LLC (Charlottesville, VA)
•University collaborators: University of Virginia and Virginia Tech
•Funding amount: $800,000
Project: Anti-bioflim enzyme (ABE) as a novel, non-toxic solution that overcomes antimicrobial resistance to protect human health from farm to fork
• Company: Lytos Technologies, LLC (Charlottesville, VA)
•University collaborators: University of Virginia and Virginia Tech
•Funding amount: $800,000
Project: Orthopaedic Surgical Site Infection Prevention via an Antibiotic Releasing Click Hydrogel
•Company: Pascal Medical Corporation (Richmond, VA)
•University collaborators: Virginia Commonwealth University and George Mason University
•Funding amount: $800,000
Project: Investigational New Drug Enabling Studies of STX2310
•Company: S1P Therapeutics Inc. (Blacksburg, VA)
•University collaborators: Virginia Tech and University of Virginia
•Funding amount: $800,000